Inventiva Sa

Inventiva Sa FCF Yield

The Free Cash Flow Yield of Inventiva Sa (IVA) as of Oct 18, 2026 is -14.82 %. In the previous year, Free Cash Flow Yield was -12.16 % — a change of 21.88% (lower).

FCF Yield

-14.82 %

YoY

21.88%

Last updated:

Free Cash Flow Yield of Inventiva Sa is 2025 -14.82 % . Free Cash Flow Yield of Inventiva Sa was 2024 -12.16 % . It decreases by 21.88% lower compared to the previous year.

The Inventiva Sa FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-4.90 USD
Jan 1, 2019
-4.02 USD
Jan 1, 2020
-4.35 USD
Jan 1, 2021
-6.79 USD
Jan 1, 2022
-6.41 USD
Jan 1, 2023
-11.58 USD
Jan 1, 2024
-12.16 USD
Jan 1, 2025
-14.82 USD
The Inventiva Sa FCF Yield history
YEARFCF YieldYoY
-14.82 %+21.88%
-12.16 %+5.00%
-11.58 %+80.60%
-6.41 %-5.55%
-6.79 %+55.96%
-4.35 %+8.21%
-4.02 %-17.88%
-4.90 %+99.40%
-2.46 %+15.52%
-2.13 %+0.91%
-2.11 %-7.01%
-2.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Inventiva Sa Stock analysis

What does Inventiva Sa do? Inventiva Sa is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases. Inventiva Sa is listed on the stock market with the ticker IVA and ISIN US46124U1079. It went public through an IPO on July 10, 2020. The company has 77 employees and operates within the Health Care sector. Its primary product development includes Lanifibranor, a peroxisome proliferator-activated receptor agonist currently in the NATiV3 Phase 3 clinical trial for treating adult patients with MASH. Additionally, the company is developing Odiparcil for mucopolysaccharidoses and has a pre-clinical program targeting TGF-ß for idiopathic pulmonary fibrosis. Inventiva Sa's website is https://inventivapharma.com. The company operates internationally, with its headquarters located in Daix, France. It is incorporated under French law, though the founding year is not specified in the provided information. The company's research and development efforts are centered on innovative therapeutic approaches for serious medical conditions. Inventiva Sa is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Inventiva Sa stock

Free Cash Flow Yield of Inventiva Sa is -14.82 % in 2025.

Free Cash Flow Yield of Inventiva Sa changed from -12.16 % to -14.82 %, representing a 21.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Inventiva Sa since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Inventiva Sa with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Inventiva Sa

All Key Metrics — Inventiva Sa